Circulating inflammatory mediators can signal neurons through a pathway in which cytokine activation of the cells of the blood-brain barrier causes the induction of the nuclear factor kappa B (NF-B), leading to the transcription of target genes, such as the one encoding cyclooxygenase 2 (COX-2), the enzyme that initiates prostaglandin formation. These active products of the arachidonate metabolism produced by the cerebral microvasculature have critical roles in initiating the neuronal responses and the neurophysiological outcomes that take place during immunogenic stimuli, including sickness behaviors, fever and increase in the hypothalamic-pituitary adrenal axis. Whether there is more than a single cell type in the blood-brain barrier responsible for the synthesis of prostanoids in the presence of circulating proinflammatory cytokines is an interesting debate that will be summarized here.
Circulating cytokines have the ability to stimulate different populations of cells in the central nervous system (CNS), including neurons and glial cells. It is generally accepted that these proinflammatory molecules cannot cross the blood-brain barrier (BBB) and they must act either indirectly in activating cells that are accessible from the systemic circulation or via structures that are devoid of BBB, namely the circumventricular organs (CVOs). Cells forming the BBB are in a privileged position to transfer the information from the circulation to the brain parenchyma and there are exciting new developments regarding the molecular events taking place in the endothelium of the cerebral arterioles, small capillaries and venules during systemic immune challenges. Cytokines, when secreted by cells of myeloid origin in the circulation, trigger a series of events in cascade leading to the mitogen-activated protein (MAP) kinases/nuclear factor kappa B (NF-B) or the janus kinase (JAK)/signal transducer and activator of transcription (STAT) transduction pathways in vascular-associated cells of the CNS. The brain blood vessels exhibit both constitutive and induced expression of receptors for different proinflammatory ligands that can stimulate these signaling molecules. Depending on the challenges and the cytokines involved, the transduction signal(s) solicited in cells of the BBB may orient the neuronal activity in a very specific manner in activating the transcription and production of soluble factors, such as prostaglandins (PGs).
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The formation of PGs is initiated by the action of cyclooxygenase (COX, also known as prostaglandin endoperoxide H-synthase or PGHS), which catalyses two separate reactions; the first being the oxygenation of arachidonic acid to the unstable PGG 2 by a cyclooxygenase function and the second, the subsequent reduction of PGG 2 leading to a more stable PGH 2 by peroxidase reaction. Although constitutive expression of the isoform COX-1 was found in various cell types, mRNA and protein levels remain somewhat unchanged during inflammatory challenges and are therefore believed to play housekeeping roles. In contrast, the COX-2 isoform is undetectable in most tissues under basal conditions, but marked transcriptional activation can be observed in macrophages and other cell types by the endotoxin lipopolysaccharide (LPS) and proinflammatory cytokines. [1] [2] [3] Interestingly, systemic inflammatory insults cause a robust transcriptional activation of COX-2 along cells of the mouse and rat microvasculature, although the intensity of the signal and the pattern of expression depend on the challenge and the dose of the inflammatory agents. [4] [5] [6] [7] [8] Intravenous (i.v.) and intraperitoneal injections of low to moderate doses of LPS (a profound activator of the acute-phase response and cytokine release), generally induce COX-2 mRNA and protein along blood vessels of the entire brain microvasculature, choroid plexus and leptomeninges. The stimulation of PGs by cells of the BBB is not uniquely observed during endotoxemia, but in other experimental models of systemic inflammation; intramuscular (i.m.) turpentine insult stimulates transcription of COX-2 gene within the microvessels, chp and leptomeninges and the signal of this transcript paralleled the inflammation of the left hind limb. 7 This experimental model induces a local tissue damage pro-voking sterile inflammation, ie an inflammatory response that develops in the absence of any microbial stimulus provoking a specific induction of interleukin-1␤ (IL-1␤) and IL-6 without any detectable IL-1␣ and tumor necrosis factor alpha (TNF-␣) production. 9 This suggests the existence of a common cascade of cytokine release, characteristic of sterile inflammation where IL-1␤ and IL-6 might play a critical role. 9 A robust COX-2 mRNA signal is also rapidly detected in the cerebral microvessels in response to i.v. IL-1␤ and TNF-␣ injection, but not following high doses of IL-6. 7 These results indicate that specific cell populations, in particular vascular-and/or perivascular-associated cells, are responsible for the central production of PGs during systemic inflammation and circulating IL-1␤ and TNF-␣ are likely to be potent mediators of this response.
What cell type(s) is(are) synthesizing COX-2 in the brain?
The cellular source of PG production by cells lining the cerebral blood vessels is currently a matter of debate and controversies. In our original report, we faced a number of problems in the identification of the cell type(s) in the brain microvasculature expressing COX-2 transcript in response to immunogenic stimuli. Indeed, COX-2 mRNA is very sensitive to the immunocytochemistry procedure and essentially vanished rending evaluation of double-labeled cells barely possible. We have then worked on the conditions of the immunocytochemistry procedure to prevent mRNA degradation and we have successfully determined that the large majority of COX-2-expressing cells were positive for a marker of the cerebral endothelium, ie von Willebrand Factor (vWF). Figure 1 (top and middle panels) shows representative examples of such dual labeling in a long blood vessel of the caudal medulla 45 min after i.v. injection of recombinant rat TNF-␣. Numerous other reports have also shown similar data that the endothelium of the cerebral blood vessels was the main source of PG production in response to systemic LPS and IL-1 treatments. 4, [10] [11] [12] [13] However, two other well-performed studies have shown evidence that COX-2-immunoreactive (ir) cells were not endothelial, but perivascular microglia and meningeal macrophages. 8, 14 However, these authors have observed, at the edge of the blood vessels, several COX-2-ir cells alone and not colocalized within microglia, 8 indicating that perivascular microglia was not the only cell type responsible for the production of PGs within the brain. In our hands, the large majority of COX-2-expressing cells were positive for vWF in response to circulating LPS, IL-1␤ and TNF-␣ and very few cells were positive for markers of microglia. Figure 2 shows the pattern of ED2-ir cells and those expressing COX-2 mRNA 3 h after a high dose of LPS (250 g 100 g -1 b.w.) injected i.p. It is interesting to note that there is very little overlap between these perivascular microglia and COX-2 cells lining the large blood vessels, although we have found in some occasions few double-labeled cells. It is difficult to explain such discrepancies between studies, but the dose, time course, the experimental models of systemic inflammation and the antisera used to reveal the specific cell types (perivascular microglia vs the endothelium) are essential elements to take into consideration. In this regard, endothelial cells and perivascular cells in the rodent brain are not simple to label and mistakes can be made in the interpretation of the exact cell type forming the BBB. Although the exact proportion of endothelial vs perivascular microglial cells may remain a matter of debate, COX-2 is produced by cells of the BBB during the acute-phase response and there is no doubt that the endothelium has the biosynthetic machinery to produce PG.
The NK-B story
A robust activation of the nuclear factor kappa B (NF-B) is also detected in the endothelium of the brain capillaries in response to different systemic inflammatory stimuli. 15 NF-B is normally present in the cytoplasm forming an inactive complex with an inhibitor known as IB␣. Following extracellular stimulation by growth factors, mitogens and cytokines that activate MAP kinases, IB␣ is phosphorylated by NF-Binducible kinase (NIK)/IB␣ kinases (IKK), unbiquitinated and degraded by cytoplasmic proteasome. 16, 17 Free active NF-B (the commonest complex is the p50/p65 heterodimer) is then translocated into the nucleus where it is able to regulate transcription of various genes in binding to its B consensus sequence. Following its degradation, IB␣ is rapidly re-synthesized to act as an endogenous inhibitory signal for NF-B and is a powerful tool to investigate the activity of the transcription factor within the CNS.
Systemic LPS and proinflammatory molecules have the ability to cause a robust transcriptional activity of IB␣ in different structures of the brain. 15, 18 The endotoxin injected either i.v. or i.p. provoked a rapid and prolonged expression of IB␣ mRNA in the endothelium of the brain blood vessels and parenchymal microglia. 15, 18 The effects of i.v. IL-1␤ and TNF-␣ also take place rapidly (within 30-60 min), but vanished 3 h after the injection. 15 On the other hand, a selective expression of IB␣ was detected along the cerebral endothelium of i.m. turpentine-injected rats. 15 The Image section (bottom right) shows that the mRNA encoding IB␣ is essentially expressed within endothelial cells of the brain irrigating system. The rapid and transient induction of IB␣ indicates a strong NF-B activity in cells of the BBB by circulating proinflammatory cytokines, which may lead to the transcription of target genes.
One potential candidate is the gene encoding COX-2; the nuclear factor binding to the COX-2 promoter is able to influence the enzyme transcription in response to different immunogenic ligands, including IL-1␤. 19, 20 The binding of IL-1␤ to its cognate type I receptor leads to the formation of the IL-1 receptor-associated kinases (IRAK)/TNF receptor-associated factor 6 (TRAF6)/ACP complex, which activates NIK/IKK kinases involved in the phosphorylation and degradation of IB␣. 16 NF-B is then translocated into the nucleus and may bind to Figure 1 Phenotype of COX-2-and IB␣-expressing cells in a rat cerebral blood vessel (bv) during systemic inflammatory insults. Endothelial cells were labeled by immunohistochemistry using antisera against the von Willebrand Factor (vWF-ir), whereas a COX-2 antibody (COX-2-ir) was used to perform the dual labeling with IB␣-expressing cells (bottom panels). COX-2 or IB␣ mRNA was thereafter hybridized on the same sections by means of a radioactive in situ hybridization technique (silver grains). Arrowheads, dual-labeled cells (endothelial/COX-2 mRNA, top and middle panels; COX-2-ir/IB␣ mRNA, bottom panels).
its B consensus sequence on target genes. 17 Two putative NF-B motifs from the COX-2 promoter were found to bind p50/p65 NF-B heterodimers in an IL-1␤-dependent manner and the two NF-B subunits synergistically activate a −917/+49 COX-2 promoter construct. 19 Figure 2 Expression pattern of perivascular microglia (ED2-ir) and COX-2 mRNA in the rat blood vessels 3 h after an intraperitoneal injection of the endotoxin lipopolysaccharide (LPS). Perivascular microglial cells were labeled by immunohistochemistry using an antisera directed against ED2. COX-2 mRNA was thereafter hybridized on the same sections via a radioactive in situ hybridization technique (silver grains). Please note that ED2-ir cells and the COX-2 hybridization signal do not overlap along the large blood vessel. White arrowheads, ED2-ir cells; black arrowheads, COX-2-expressing cells.
also been observed in response to circulating LPS, 7, 15, 22 but it is not well known how cell activation is triggered after binding between the LPS/LBP complex and the glycosyl-phosphatidylinositol (GPI)-anchored mCD14. Moreover, endothelial cells do not express membrane CD14, although these cells respond to LPS/LBP in a soluble (s)CD14-dependent manner in stimulating the tyrosine phosphorylation of MAP kinases. 23 The recent characterization of human homologues of Toll (TLR1/6) may be the missing link for the transduction events leading to NF-B activity induced by LPS and proinflammatory cytokines. 24 The NF-B site (−223 to −214) is also involved in LPS-induced expression of COX-2 in monocytic cells, 25 whereas hypoxia induces COX-2 transcription via p65 binding to the 3ЈNF-B consensus element in the enzyme upstream promoter region in endothelial cells. 26 We have recently found colocalization between the IB␣ transcript and COX-2 protein, indicating a potential interaction between the transcription factor and COX-2 in the brain vascular cells of immune-challenged animals (see Figure 1 , bottom panels). Obviously, this remains speculative from these anatomical data and the signaling pathways that lead to the NF-B nuclear translocation and COX-2 transcription have yet to be determined in the cells of the BBB. In vivo approaches are quite limited in the investigation of the intracellular events occurring within specific cellular populations of the CNS, but they provide an essential integration of the systems that interact during the acute-phase response.
What are the functional consequences of PG production by cells of the BBB?
Blockage of the eicosanoid cyclooxygenase pathways can prevent the stimulation of cortiocotropin-releasing factor (CRF) release by proinflammatory cytokines from in vitro hypothalamic explants 27, 28 and median eminence, 29 and IL-1-30,31 and TNF-␣ 32 induced ACTH release in vivo. The exact PG subtype(s) and the site(s) of action involved in these effects still remain unclear, but a large body of evidence indicates that PG of E 2 type is a key molecule in the transfer of information received from circulating cytokines and foreign materials to parenchymal cells of the brain. IL-1 increases the release of PGE 2 from rat hypothalamic explants in vitro 33 and numerous regions of the brain in vivo, including the paraventricular nucleus of the hypothalamus (PVN). 34 Intracerebral administration of PGE 2 elevates plasma ACTH and corticosterone 35, 36 and causes a selective cellular activation as indicated by the rapid and transient expression of the immediateearly gene (IEG) c-fos mRNA and its protein product within multiple regions of the brain recognized to be activated during the acute-phase response. 37, 28 Local production of PGE 2 might therefore be a crucial step within the CNS to mediate the effects of circulating cytokines on the neuronal circuitry involved in the activation of the hypothalamic-pituitary-adrenal (HPA) axis and other autonomic functions. As mentioned, the microvasculature is the source of PG formation into the brain during systemic inflammatory challenges. It is interesting to note that inflammation-induced COX-2 is rather unspecific across the cerebral blood vessels and small capillaries, while the neuronal activity is limited to selective nuclei, including the endocrine hypothalamus. It is consequently possible that expression of specific PGE 2 receptors within parenchymal cells adjacent to the site of production determines the action of the PG in the brain.
The actions of PGE 2 are mediated by their specific seven-transmembrane receptors divided into four subtypes, ie EP [1] [2] [3] [4] . Three isoforms of the EP 3 receptors have been identified (EP 3␣ , 3␤ , 3␥ ), which share common extracellular and membrane-spanning regions, but differ in intracellular and carboxyterminal domains. These receptor variants are generated by alternative splicing of the primary transcript and are associated to different G proteins, like the other subtypes. These receptors trigger different transduction signals; EP 1 , EP 2 and EP 3 are coupled to stimulation of phospholipase C, and stimulation and inhibition of adenylate cyclase, respectively. The most recently identified subtype, EP 4 , is like the EP 2 receptor positively coupled to adenylate cyclase. 39, 40 We have recently observed a very distinct pattern of EP 2 and EP 4 expression in the rat brain under both basal and immune-challenged conditions and underlined the possible role of the EP 4 subtype in mediating the effects of PGE 2 on different autonomic and neuroendocrine functions. 41 The presence of Fos-ir nuclei in various populations of EP 4 neurons of IL-1-treated animals clearly supports this concept and suggests that the selectivity of the neuronal response during systemic inflammation may depend on the expression of specific PGE 2 receptors in key structures of the brain.
Where do we go from now?
We know a little more on the site(s) of action and the neuronal pathways participating in the influence of circulating cytokines on the brain functions fundamental to restoring homeostasis during immunogenic stimuli. Obviously, investigating the transduction signals involved in these events is somewhat limited in vivo, though the time-related induction of specific signaling molecules within the same population(s) of cells will be crucial information for future directions. The participation of the endothelium, microglia or other cell types lining the BBB may depend on numerous factors, including the severity and duration of the inflammatory insults as well as the model of the systemic immunogenic challenges. Although the intracellular events may largely differ among stimuli and endogenous ligands, the resulting production of PGE 2 is likely to be the critical link between the circulating immune molecules and parenchymal elements of the brain to activate the neuronal circuits controlling different neurophysiological and neuroendocrine functions. The HPA axis is one of these functions having a profound impact in regulating the inflammation. Inappropriate plasma levels of glucocorticoids may play a crucial role in contributing to deviant regulation of the immune response, indicating the importance of identifying and characterizing the mechanisms through which inflammatory molecules interact with, and depend on, the neuroendocrine system. Disorders of this fine interplay may indeed contribute to the onset and progression of various pathological states characterized by an exaggerated inflammatory response in the periphery as well as in the CNS. 
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